Zymeworks

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

Trellis Bioscience provides healthcare products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments. The company was founded in 1998 and is based in Redwood City, California.

BioPro Pharmaceutical is the first regional biotech company in Asia to develop, market leading biopharmaceutical medicines, as well as many of the world's best known biopharmaceutical products. BioPro Pharmaceutical , Inc. has infrastructure in place in all major countries in Asia to target the market of US$30 billion. BioPro's expertise is in providing creative pharmaceutical solutions to small and medium-sized US or European companies by integrating Asia's respective business strengths in addressing the pharmaceutical needs of the Asia-Pacific region. We have the knowledge and know-how of the clinical and regulatory requirements across the Asian region . We manage more than 600 professional sales representatives. We are focused on the marketing and distribution of innovative biotech cancer products in Asian markets with the most cost-effective approaches. We anticipate intense competition in this new market sector, and are working diligently to stay at the forefront of this everchanging competitive environment. BioPro obtained the exclusive rights for the core patented technology - High Throughput Mammalian Protein Expression technology to develop cost effective protein products for bioassay and reagent support and " rapid mammalian production cell development technology and downstream support team for new generations of currently well-known and future protein drugs; We have three protein therapeutics, two antibody therapeutics and two vaccines under development.